DOTATATE

DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) [1][2][3][4]. DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

Product Specifications

CAS Number

[177943-88-3]

UNSPSC

12352209

Hazard Statement

H302, H312, H332

Target

Radionuclide-Drug Conjugates (RDCs)

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dotatate.html

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)NC([C@H](NC(CN2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(C=C4)O)N[C@@H]1CC5=CNC6=CC=CC=C56

Molecular Formula

C65H90N14O19S2

Molecular Weight

1435.62

Precautions

H302, H312, H332

References & Citations

[1]Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S.|[2]Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10.|[3]Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30 (6) :917-20.|[4]Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27 (3) :273-82.